Chronic hepatitis B virus infection: Treatment strategies for the next millennium

Annals of Internal Medicine

Volumn 132, Issue 9, 2000, Pages 723-731

  Malik, Arshad H ^a   Lee, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; DIDANOSINE; DNA POLYMERASE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FIALURIDINE; GANCICLOVIR; IMMUNOMODULATING AGENT; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE ANALOG; RIBAVIRIN; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CHRONIC DISEASE; CHRONIC HEPATITIS; DOSE RESPONSE; DRUG EFFECT; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0034595367     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-9-200005020-00007     Document Type: Review

References (100)

1. Hoofnagle JH. Chronic hepatitis B [Editorial]. N Engl J Med. 1990;323: 337-9 .
2. Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med. 1994;10(Suppl): 45-55.
3. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-45.
4. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):47-9.
5. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276:906-8.
6. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991;40:1-25.
7. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med. 1981;94:744-8.
8. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588-91.
9. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347-56.
10. Fried MW. Therapy of chronic viral hepatitis. Med Clin North Am. 1996;80: 957-72.
11. Peters M. Mechanism of action of interferons. Semin Liver Dis. 1989;9: 235-9.
12. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res. 1999; 19:817-28.
13. Kuhen KL, Vessey JW, Samuel CE. Mechanism of interferon action: identification of essential positions within the novel 15-base-pair KCS element required for transcriptional activation of the RNA-dependent protein kinase pkr gene. J Virol. 1998;72:9934-9.
14. Kuhen KL, Samuel CE. Mechanism of interferon action: functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter. Virology 1999;254:182-95.
15. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol. 1998;25(Suppl 1):23-9.
16. Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology. 1986;90:150-7.
17. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology. 1988;95:1318-25.
18. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323:295-301.
19. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol. 1993;88:1887-92.
20. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119:312-23.
21. Perrillo RP. The use of corticosteroids in conjunction with antiviral therapy in chronic hepatitis B with ongoing viral replication. J Hepatol. 1986;3(Suppl 2):S57-S64.
22. Perrillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, Campbell CR, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med. 1988;109:95-100.
23. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology. 1994;20:1390-8.
24. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422-7.
25. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577-80.
26. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995; 109:908-16.
27. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761-3.
28. Lok AS, Weller IV, Karayiannis P, Brown D, Fowler MJ, Monjardino J, et al. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver. 1984;4:45-9.
29. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993;104:1116-21.
30. Paar DP, Hooton TM, Smiles KA, Di Bisceglie A, Havlir DV, Richman DD, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HIV-infected subjects (ACTG 122b) [Abstract]. In: Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 10-14 October 1992. Washington, DC: American Soc for Microbiology; 1992:264.
31. Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Beames MP, Hoofnagle JH. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B [Abstract]. Hepatology. 1992;16: 127A.
32. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099-105.
33. Josefson D. Oral treatment for hepatitis B gets approval in the United States. BMJ. 1998;317:1034.
34. Schalm SW, de Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol. 1995;22(Suppl 1):52-6.
35. Cammack N, Rouse P, Marr CL, Reid PJ, Boehme RE, Coates JA, et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol. 1992;43:2059-64.
36. Honkoop P, de Man RA, Niesters HG, Main J, Nevens F, Thomas HC, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepat. 1998;5:307-12.
37. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66.
38. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-61.
39. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997;113:1258-63.
40. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
41. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-63
42. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [Abstract]. International Lamivudine Investigator Group. Hepatology. 1998;28:388A.
43. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5.
44. Perrillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations [Editorial]. Hepatology. 1990; 12:1433-5.
45. Leung N, Wu PC, Tsang S, Chan HL, Dent J, Roman L, et al. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine [Abstract]. Hepatology. 1998;28:489A.
46. Liaw YF, Lai CL, Leung NW, Chang TT, Guan R, Tai DI, et al. Two year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicenter study in Asia [Abstract]. Gastroenterology. 1998;114: A1289.
47. Schiff E, Cianciara J, Kowdley K, Norkrans G, Perrillo R, Tong M, et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. International Lamivudine Investigator Group [Abstract]. Hepatology. 1998;28:163A.
48. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 1993;105:845-50.
49. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology. 1989;10: 198-202.
50. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889-96.
51. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30:770-4.
52. Leung N, Dienstag J, Schiff E, Sullivan M, Atkins M, Grice R, et al. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients [Abstract]. Hepatology. 1998;28:587A.
53. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27:1670-7.
54. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis. 1998;177:1382-5.
55. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol. 1998;55:1567-72.
56. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients [Abstract]. Hepatology 1998;28:319A.
57. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol. 1997;26:1393-5.
58. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 1998;27:628-33.
59. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 1998;27:1711-6.
60. Heathcote J, Chan R, McHutchinson J, Lee WM, Sherman M, Rutkiewicz V, et al. A phase 2 multi-center study of oral lobucavir for treatment of chronic hepatitis B. Lobucavir HBV Study Group [Abstract]. Hepatology. 1998;28:318A.
61. Bloomer J, Brennan-Rowe N, Denisky G, Bukenya T, Rutkiewicz V, Joshi S, et al. Extended treatment of chronic hepatitis B with oral lobucavir: safety and efficacy. Lobucavir Hepatitis Study Group [Abstract]. Hepatology. 1998;28:486A.
62. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997;40:337-42.
63. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study [Abstract]. Hepatology. 1996;24: 188A.
64. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat. 1996;3:211-5.
65. Lai CL, Yuen MF, Cheng CC, Wong WM, Cheng TK, Lai YP. An open comparative study of lamivudine and famciclovir for the treatment of chronic hepatitis B infection [Abstract]. Hepatology. 1998;28:490A.
66. Wolters LM, Honkoop P, Niesters HG, de Man RA. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene. J Hepatol. 1998;28:909-10.
67. De Clerq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides. 1994;13:1271-95.
68. Gilson RJ, Chopra K, Murray-Lyon IM, Newell AM, Nelson MR, Tedder RS, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection [Abstract]. Hepatology. 1996;24:281A.
69. Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D. A preliminary study of lobucavir for chronic hepatitis B [Abstract]. Hepatology. 1997; 26:428A.
70. Jeffers J, Heathcote E, Wright T, Carithers R, Di Bisceglie A, Perrillo R, et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection [Abstract]. Antiviral Res. 1998;37:A197.
71. Gilson RJ, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Murray A, et al. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection [Abstract]. Hepatology. 1998;28:491A.
72. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II and III trials. Adefovir Dipivoxil HBV Study Team [Abstract]. Hepatology. 1998:28:317A.
73. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999;282:2305-12.
74. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Kato J, et al. Susceptibility of lamivudine resistant hepatitis B virus to other antivirals: adefovir and lobucavir [Abstract]. Hepatology. 1998;28:165A.
75. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology. 1998;28:1669-73.
76. Xiong X, Yang H, Westland CE, Toole JJ, Gibbs CS. Human hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir [Abstract]. Hepatology. 1998;28:491A.
77. Perrillo R, Schiff E, Magill A, Murray A. In vivo demonstration of sensitivity of YMDD variants to adefovir [Abstract]. Gastroenterology. 1999;116: A1261.
78. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol. 1995;17:261-81.
79. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology.1991; 14:409-15.
80. Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare E, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody -and hepatitis B virus DNA - positive chronic hepatitis B. Hepatology. 1996; 24:774-7.
81. Chien RN, Liaw YF, Chen TC, Yen CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27:1383-7.
82. Fattovich G, Giustina G, Alberti A, Guido M, Pontisso P, Favarato S, et al. A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. J Hepatol. 1994;21:361-6.
83. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appleman HD. Thymosin alpha 1 treatment of chronic hepatitis B: a multicenter, randomized, placebo-controlled double-blind study [Abstract]. Gastroenterology. 1995;108:A1127.
84. Andreone P, Cursaro C, Gramenzi A, Buzzi A, Covarelli MG, Di Giammarino L, et al. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver. 1996;16:207-10.
85. Tang JH, Yeh CT, Chen TC, Hsieh SY, Chu CM, Liaw YF. Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B. J Infect Dis. 1998;178:866-9.
86. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Vaccination against hepatitis B virus: an efficient immunotherapy against hepatitis B multiplication. Comptes Rendus de l'Académie des Sciences Paris. 1993,316: 688-91.
87. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A. 1996;93:12496-501.
88. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest. 1995;95:341-9.
89. Heathcote J, McHutchison J, Benner K, Wright T, Minuk J, Sacks S, et al. CY-1899: a therapeutic vaccine for chronic hepatitis B [Abstract]. Hepatology. 1996;24:283A.
90. Pol S, Driss F, Couillin I, Denis J, Tiollais P, Michel ML, et al. A controlled study of anti-HBV vaccine therapy in chronic hepatitis B infection [Abstract]. Hepatology. 1998;28:488A.
91. Senturk H, Tabak F, Akdogan M, Melt A, Erdem L, Turkoglu S, et al. Therapeutic vaccination with a pre-52 containing vaccine in chronic hepatitis B: a promising approach [Abstract]. Hepatology. 1998;28:588A.
92. Putlitz J, Skerra A, Wands JR. An intracellular antibody fragment inhibits hepatitis B virus surface antigen secretion [Abstract]. Hepatology. 1998;28: 590A.
93. Heathcote J, Schalm SW, Cinciara J, Farrell G, Feinmann V, Shermann M, et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection [Abstract]. J Hepatol. 1998;28:43.
94. Marques AR, Lau DT, McKenzie R, Straus SE, Hoofnagle JH. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis. 1998;178:1483-7.
95. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997;26:216-25.
96. Leung YK, So T. Treatment of chronic hepatitis B using thymosin alpha 1 and a combination of two nucleoside analogs, lamivudine and famciclovir [Abstract]. Hepatology. 1998;28:216A.
97. Lau GK, Kwok A, Karlberg J, Lai ST, Lim W, Leung YK, et al. A twenty six weeks trial of thymosin alpha 1 plus famciclovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B [Abstract]. Hepatology. 1998;28:216A.
98. Lacey LF, Cox FM, Payne SL. A drug budget perspective of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States [Abstract]. Hepatology. 1999;30:481A.
99. Drugs for non-HIV viral infections. Med Lett. 1999;41:113-20.
100. Haiderali AM, Villa K, Schrammel P. Cost effectiveness of lamivudine for the treatment of chronic hepatitis B in Canada [Abstract]. Hepatology. 1999; 30:347A.